Dulaglutide reduced lung damage, inflammatory cytokines, immune cell infiltration, and cell death in a mouse model of sepsis-induced lung injury through inhibition of STAT3 and NLRP3 signaling pathways.
STAT3 and NLRP3 suppressedDulaglutide's lung protection in sepsis was mediated through two specific signaling pathways — phosphorylated STAT3 and the NLRP3 inflammasome — both established drug targets in inflammatory disease.
What the researchers found
In mice with LPS-induced sepsis (15 mg/kg), dulaglutide (0.6 mg/kg daily) produced multiple protective effects in the lungs:
- Improved weight loss and reduced overall lung injury
- Reversed increases in six inflammatory mediators: IL-1β, TNF-α, IL-6, CXCL1, CCL2, and CXCL2
- Reduced neutrophil and macrophage infiltration in lung tissues
- Reversed apoptosis markers: reduced caspase-3, cleaved caspase-3, caspase-8 expression; restored Bcl-2/Bax ratio; reduced TUNEL-positive (dying) cells
- Reduced expression of P-STAT3 (phosphorylated STAT3) and NLRP3 inflammasome — identified as potential therapeutic targets for sepsis lung injury
These results demonstrate dual anti-inflammatory and anti-apoptotic mechanisms of GLP-1 receptor activation in acute lung injury.
Why it matters
Sepsis kills approximately 11 million people annually worldwide, and acute lung injury is a leading cause of sepsis mortality. Current treatment is primarily supportive — there are no approved drugs that specifically target sepsis-induced lung damage. The discovery that a widely available GLP-1 drug protects lungs through specific molecular pathways (STAT3 and NLRP3) opens the possibility of repurposing existing diabetes medications for critical care, potentially saving lives with an already safety-tested drug.
How the study worked
Mice were given LPS (lipopolysaccharide, 15 mg/kg intraperitoneally daily) to induce sepsis-related acute lung injury. Dulaglutide (0.6 mg/kg daily intraperitoneally) was administered as treatment. Researchers measured body weight changes, lung tissue histopathology, inflammatory cytokine and chemokine expression (IL-1β, TNF-α, IL-6, CXCL1, CCL2, CXCL2), immune cell infiltration (neutrophils, macrophages), apoptosis markers (caspase-3, cleaved caspase-3, caspase-8, Bcl-2/Bax ratio), TUNEL staining for cell death, and signaling pathway proteins (P-STAT3, NLRP3).
What this study cannot tell us
This is a mouse study using LPS injection to model sepsis, which differs from human sepsis caused by live bacterial infection. The LPS model produces a more predictable but less complex inflammatory response than actual sepsis. Dulaglutide was administered concurrently with LPS (prophylactic/treatment timing not clearly separated), so it's unclear whether the drug would work if given after sepsis is already established. The 0.6 mg/kg dose in mice may not translate directly to human dosing. No survival data were reported. The study did not assess whether dulaglutide affected bacterial clearance, which could be important in real sepsis.
How to read the evidence
This is a preclinical animal study using an established LPS-induced sepsis model with comprehensive inflammatory, apoptotic, and signaling pathway assessments. While the mechanistic evidence is thorough, all findings are in mice and the model is a simplification of human sepsis.
When this study was published
Published in 2023, this is a recent study contributing to the expanding understanding of GLP-1 drugs' anti-inflammatory potential in acute critical illness.
The bigger picture
This study adds sepsis-induced lung injury to the rapidly growing list of conditions where GLP-1 drugs show protective anti-inflammatory effects — joining cardiovascular disease, kidney disease, neurodegeneration, and liver disease. The identification of STAT3 and NLRP3 as specific pathways is significant because both are well-known drug targets with existing pharmacological tools. The convergence of GLP-1 receptor activation with inflammasome suppression suggests these peptide drugs may represent a new class of anti-inflammatory agents for acute critical illness.
Questions still open
- Would dulaglutide be protective if administered after the onset of sepsis rather than concurrently with LPS?
- Do diabetic patients on GLP-1 drugs have lower rates of sepsis-related organ failure — could real-world data support this finding?
- Could GLP-1 receptor agonists be tested in clinical trials as adjunctive therapy for sepsis patients in the ICU?
Common questions
How does a diabetes drug protect the lungs from sepsis?
Could GLP-1 drugs be used in the ICU for sepsis patients?
Read the original research
Dulaglutide provides protection against sepsis-induced lung injury in mice by inhibiting inflammation and apoptosis.
European journal of pharmacology, 949, 175730
Citation
Wang, Yue; Deng, Fengyi; Zhong, Xing; Du, Yijun; Fan, Xingyu; Su, Hong; Pan, Tianrong. (2023). Dulaglutide provides protection against sepsis-induced lung injury in mice by inhibiting inflammation and apoptosis.. European journal of pharmacology, 949, 175730. https://doi.org/10.1016/j.ejphar.2023.175730